Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas

Abstract

Introduction In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods The retrospective data analysis was based on data that were collected for the multicenter study “Role of surgical treatment for non-colorectal liver metastases” in county Thuringia. Results For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.

Histopathological growth pattern of liver metastases as an independent marker of metastatic behavior in different primary cancers

“…This is also the case in patients with LM from diverse primary cancers of digestive and non-digestive origins, frequently regrouped as non-colorectal LM. In these cases, even if their indications remain ill-defined, local approaches, including surgical resection, are now more frequently used, aiming to enhance overall tumor control but also potentially leading to prolonged progression-free survival (3)(4)(5)(6)(7)(8)(9). This suggests that, beyond the variability of primary tumors and selection processes, a fraction of these patients with isolated LM could share similar characteristics of restricted metastatic progression, so-called "oligo"or "argo-metastasis" (10-12).…”